$REGN REGENERON PHARMACEUTICALS, INC. Insider Trading Week 49/2020
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in REGENERON PHARMACEUTICALS, INC..
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of insider trading in REGENERON PHARMACEUTICALS, INC. in week 49/2020.
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 11 2020 | REGN | REGENERON PHARMACE ... | MURPHY ANDREW J | EVP Research | Option Exercise | A | 492.00 | 25,000 | 12,300,000 | 25,000 | |
| Dec 11 2020 | REGN | REGENERON PHARMACE ... | MURPHY ANDREW J | EVP Research | Grant | A | 0.00 | 1,929 | 0 | 57,350 | 55.4 K to 57.4 K (+3.48 %) |
| Dec 11 2020 | REGN | REGENERON PHARMACE ... | MURPHY ANDREW J | EVP Research | Grant | A | 0.00 | 8,285 | 0 | 55,421 | 47.1 K to 55.4 K (+17.58 %) |
| Dec 11 2020 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Director | Option Exercise | A | 492.00 | 27,680 | 13,618,560 | 27,680 | |
| Dec 11 2020 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Director | Gift | G | 0.00 | 2,406 | 0 | 3,609 | 1.2 K to 3.6 K (+200.00 %) |
| Dec 11 2020 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Director | Gift | G | 0.00 | 2,406 | 0 | 47,786 | 50.2 K to 47.8 K (-4.79 %) |
| Dec 11 2020 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Director | Gift | G | 0.00 | 349 | 0 | 143,210 | 143.6 K to 143.2 K (-0.24 %) |
| Dec 11 2020 | REGN | REGENERON PHARMACE ... | VAGELOS P ROY | Director | Grant | A | 0.00 | 2,439 | 0 | 237,088 | 234.6 K to 237.1 K (+1.04 %) |
| Dec 11 2020 | REGN | REGENERON PHARMACE ... | Van Plew Daniel P | EVP & General Mgr I ... | Option Exercise | A | 492.00 | 19,950 | 9,815,400 | 19,950 | |
| Dec 11 2020 | REGN | REGENERON PHARMACE ... | Van Plew Daniel P | EVP & General Mgr I ... | Grant | A | 0.00 | 5,000 | 0 | 26,931 | 21.9 K to 26.9 K (+22.80 %) |
| Dec 11 2020 | REGN | REGENERON PHARMACE ... | Van Plew Daniel P | EVP & General Mgr I ... | Grant | A | 0.00 | 1,930 | 0 | 21,931 | 20 K to 21.9 K (+9.65 %) |
| Dec 11 2020 | REGN | REGENERON PHARMACE ... | McCourt Marion | SVP Commercial | Option Exercise | A | 492.00 | 25,000 | 12,300,000 | 25,000 | |
| Dec 11 2020 | REGN | REGENERON PHARMACE ... | McCourt Marion | SVP Commercial | Grant | A | 0.00 | 2,000 | 0 | 17,038 | 15 K to 17 K (+13.30 %) |
| Dec 11 2020 | REGN | REGENERON PHARMACE ... | McCourt Marion | SVP Commercial | Grant | A | 0.00 | 1,075 | 0 | 15,038 | 14 K to 15 K (+7.70 %) |
| Dec 11 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Option Exercise | A | 492.00 | 17,500 | 8,610,000 | 17,500 | |
| Dec 11 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Grant | A | 0.00 | 1,688 | 0 | 24,715 | 23 K to 24.7 K (+7.33 %) |
| Dec 11 2020 | REGN | REGENERON PHARMACE ... | STAHL NEIL | EVP Research and De ... | Gift | G | 0.00 | 750 | 0 | 20,979 | 21.7 K to 21 K (-3.45 %) |
| Dec 11 2020 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Option Exercise | A | 492.00 | 10,000 | 4,920,000 | 10,000 | |
| Dec 11 2020 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Gift | G | 0.00 | 25 | 0 | 25 | 0 to 25 |
| Dec 11 2020 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Gift | G | 0.00 | 25 | 0 | 25 | 0 to 25 |
| Dec 11 2020 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Gift | G | 0.00 | 50 | 0 | 0 | 50 to 0 (-100.00 %) |
| Dec 11 2020 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Grant | A | 0.00 | 1,750 | 0 | 21,102 | 19.4 K to 21.1 K (+9.04 %) |
| Dec 11 2020 | REGN | REGENERON PHARMACE ... | Fenimore Christopher R. | VP Controller | Grant | A | 0.00 | 969 | 0 | 19,352 | 18.4 K to 19.4 K (+5.27 %) |
| Dec 11 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Option Exercise | A | 492.00 | 19,950 | 9,815,400 | 19,950 | |
| Dec 11 2020 | REGN | REGENERON PHARMACE ... | Landry Robert E | EVP Finance CFO | Grant | A | 0.00 | 1,930 | 0 | 25,903 | 24 K to 25.9 K (+8.05 %) |
| Dec 11 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Option Exercise | A | 492.00 | 19,950 | 9,815,400 | 19,950 | |
| Dec 11 2020 | REGN | REGENERON PHARMACE ... | LAROSA JOSEPH J | EVP General Counsel ... | Grant | A | 0.00 | 1,930 | 0 | 16,368 | 14.4 K to 16.4 K (+13.37 %) |